Immediate Treatment for Hyperkalemia

Assessment of Severity

The European Society of Cardiology recommends that mild hyperkalemia be defined as a potassium level of 5.0-5.9 mEq/L 1
The European Society of Cardiology recommends that moderate hyperkalemia be defined as a potassium level of 6.0-6.4 mEq/L 1
The American Heart Association recommends that severe hyperkalemia be defined as a potassium level of ≥6.5 mEq/L, which is life-threatening 1, 2
ECG changes, such as peaked T waves, flattened P waves, prolonged PR interval, and widened QRS, indicate urgent treatment regardless of potassium level, according to the American Heart Association 2

Step 1: Cardiac Membrane Stabilization

The American Heart Association recommends intravenous calcium, such as calcium chloride (10%): 5-10 mL (500-1000 mg) IV over 2-5 minutes, to protect the heart 2
The American Heart Association recommends intravenous calcium gluconate (10%): 15-30 mL IV over 2-5 minutes, as an alternative to calcium chloride 2
The European Society of Cardiology notes that the effects of calcium administration begin within minutes but are temporary, lasting 30-60 minutes 1, 2
The American Heart Association states that calcium administration does not lower serum potassium but protects against arrhythmias 2

Step 2: Shift Potassium into Cells

The American Heart Association recommends insulin with glucose, such as 10 units regular insulin IV with 25g glucose (50 mL of D50W) over 15-30 minutes, to shift potassium into cells 2
The European Society of Cardiology notes that the onset of insulin and glucose is within 15-30 minutes, and the effect lasts 4-6 hours 1, 2
The American Heart Association recommends nebulized albuterol: 10-20 mg over 15 minutes, as a beta-2 adrenergic agonist to shift potassium into cells 2
The European Society of Cardiology notes that sodium bicarbonate is most effective in patients with concurrent metabolic acidosis, and recommends 50 mEq IV over 5 minutes 1, 2

Step 3: Eliminate Potassium from Body

The American Heart Association recommends loop diuretics, such as furosemide: 40-80 mg IV, to eliminate potassium from the body, effective only in patients with adequate renal function 1, 2
The American Heart Association recommends cation exchange resins, such as sodium polystyrene sulfonate (Kayexalate): 15-50 g orally or rectally with sorbitol, to eliminate potassium from the body 2
The European Society of Cardiology notes that newer potassium binders, such as patiromer and sodium zirconium cyclosilicate, are safer alternatives to traditional cation exchange resins 1
The American Heart Association recommends hemodialysis as the most effective method for severe hyperkalemia, especially in patients with renal failure 2

Important Clinical Considerations

The European Society of Cardiology notes that temporary measures, such as insulin/glucose and albuterol, provide only transient effects (1-4 hours), and rebound hyperkalemia can occur after 2 hours 1
The European Society of Cardiology recommends that treatment with potassium-lowering agents should be initiated as early as possible to prevent rebound 1
The European Society of Cardiology notes that monitoring potassium levels closely during treatment is crucial to avoid overcorrection and hypokalaemia 3
The European Society of Cardiology recommends reviewing and adjusting medications that may contribute to hyperkalemia, such as ACE inhibitors, ARBs, MRAs, NSAIDs, and beta-blockers 4

Management of Hyperkalemia

Chronic or Recurrent Hyperkalemia Management

For patients on RAAS inhibitors with hyperkalemia >5.0 mEq/L, the European Society of Cardiology recommends initiating an approved potassium-lowering agent, closely monitoring potassium levels, and maintaining RAAS inhibitor therapy unless alternative treatable etiology is identified 5
For severe hyperkalemia (>6.5 mEq/L) in patients on RAAS inhibitors, the European Society of Cardiology suggests discontinuing or reducing RAAS inhibitor, initiating potassium-lowering agent when levels >5.0 mEq/L, and monitoring potassium levels closely 5

Treatment of Hyperkalemia with Fenoterol Nebulization

Mechanism of Action and Efficacy

The American Heart Association recommends beta-2 agonists, such as fenoterol, to stimulate the Na+/K+-ATPase pump, promoting the displacement of extracellular potassium into cells, thereby reducing serum potassium levels 6
Beta-2 agonists like fenoterol have a hypokalemic effect that begins within 15-30 minutes after administration and can last between 4-6 hours, providing a temporary benefit 7
The European Society of Cardiology suggests that fenoterol, like other beta-agonists, does not increase potassium excretion, providing a temporary benefit and potentially leading to rebound hyperkalemia after 2 hours 7

Clinical Use of Fenoterol Nebulization

The American College of Cardiology recommends a dose of 10-20 mg of nebulized beta-agonists, such as albuterol, administered over 15 minutes 6
The European Heart Journal suggests that fenoterol nebulization should be considered as part of a stepped therapeutic approach to hyperkalemia 7

Treatment Algorithm for Hyperkalemia

The American Heart Association recommends the following steps for hyperkalemia treatment:
- Insulin with glucose: 10 units of regular insulin IV with 25g of glucose (50 ml of D50W) over 15-30 minutes 6
- Beta-2 agonists nebulized (fenoterol or albuterol): 10-20 mg nebulized over 15 minutes 6
- Sodium bicarbonate: 50 mEq IV over 5 minutes (especially if metabolic acidosis is present) 6
- Loop diuretics (furosemide 40-80 mg IV) to increase renal potassium excretion 6
- Cation exchange resins or new potassium binders 7
- Hemodialysis in severe or refractory cases 6

Comparative Efficacy

Studies have shown that nebulized beta-2 agonists can reduce serum potassium by approximately 0.5-1.0 mEq/L, although the specific study is not cited here, the European Heart Journal provides context for the use of beta-2 agonists in hyperkalemia treatment 7

Calcium Chloride vs Calcium Gluconate in Treatment of Hyperkalemia

Comparison of Calcium Salts

The American Heart Association recommends calcium chloride (10%): 5-10 mL (500-1000 mg) IV over 2-5 minutes as first-line treatment for cardiac membrane stabilization in hyperkalemia 8
Calcium chloride provides a more rapid increase in ionized calcium concentration than calcium gluconate, making it more effective in critically ill patients 9, 10, 11

Dosing Considerations

For pediatric patients, the American Academy of Pediatrics recommends calcium chloride dosing is 20 mg/kg (0.2 mL/kg for 10% CaCl₂) 9, 10, 11
For adults, the American Heart Association recommends calcium chloride 10% at 5-10 mL (500-1000 mg) IV over 2-5 minutes 8

Administration Considerations

Calcium chloride administration should be through a central venous catheter when possible, as extravasation through a peripheral IV line may cause severe skin and soft tissue injury 9, 10, 11
Monitor heart rate during calcium administration and stop injection if symptomatic bradycardia occurs 9, 10, 11

Clinical Efficacy

Calcium administration does not lower serum potassium but protects against cardiac arrhythmias by stabilizing cardiac membranes, according to the American Heart Association 8

Complete Hyperkalemia Management Algorithm

Cardiac membrane stabilization (immediate effect): Calcium chloride (10%): 5-10 mL IV over 2-5 minutes (preferred) 8
Eliminate potassium from body (longer-term effect): Cation exchange resins or newer potassium binders may be used, as noted in the Mayo Clinic Proceedings 12
Shift potassium into cells (effect within 15-30 minutes): Insulin with glucose, nebulized albuterol, or sodium bicarbonate may be used, as recommended by the American Heart Association 8

Treatment of Hyperkalemia

Introduction to Hyperkalemia Management

The European Heart Journal recommends that in patients on RAAS inhibitors with cardiovascular disease, maintaining these life-saving medications by using potassium binders is preferable to discontinuing therapy, to avoid rebound hyperkalemia 13, 14

Critical Clinical Considerations

It is crucial to exclude pseudo-hyperkalemia from hemolysis or improper sampling before initiating aggressive treatment, as stated in the European Heart Journal 14

Hyperkalemia Treatment Guidelines

Dextrose Concentration and Dosage

The American Academy of Pediatrics recommends using dextrose concentrations of 200 mg/kg as D10W for hyperkalemia treatment in pediatric patients, emphasizing the importance of specific dextrose concentrations 15, 16
To deliver 25g of glucose, 500 mL of D5 solution would be required, compared to 50 mL of D50W, highlighting the need for concentrated dextrose solutions 16

Dextrose Formulations

The American Academy of Pediatrics suggests using D25W (25% dextrose) as an acceptable alternative to D50W, with 100 mL providing 25g glucose 15, 16

DNR Orders Do Not Preclude Urgent Dialysis for Severe Hyperkalemia

Scope of DNR Orders

DNR orders are procedure‑specific and apply only to cardiopulmonary resuscitation in the event of cardiac or pulmonary arrest, not to other medical interventions【17】.
The American Heart Association states that a DNR or DNI status does not limit the use of treatments such as vasopressors, supplemental oxygen, or electrolyte replacement【18】.
Misinterpretation of DNR orders frequently leads to less aggressive care beyond resuscitation, including reduced admission to specialized units and fewer guideline‑concordant procedures【17】.
Decisions to limit specific medical or surgical therapies should be addressed in separate shared‑decision‑making discussions with the patient or surrogate【17】.

Compatibility of Dialysis with DNR Status

For patients with end‑stage renal disease (ESRD) and life‑threatening hyperkalemia, dialysis is considered a standard medical treatment rather than a resuscitative measure and is fully compatible with an existing DNR order【19】【20】.
The American Heart Association recommends continuous renal replacement therapy (CRRT) over intermittent dialysis when the patient is hemodynamically unstable【19】.
Although ESRD patients requiring dialysis have a higher mortality risk, dialysis remains appropriate when it aligns with the patient’s goals of care【20】.
Initiation or continuation of dialysis should be guided by patient‑centered goals, quality‑of‑life considerations, and overall prognosis【20】.
Discontinuation of dialysis is a distinct decision from DNR status and must undergo its own shared‑decision‑making process【20】.

Decision‑Making and Patient Autonomy

A competent adult patient retains the right to make her own medical decisions; a DNR order she signs pertains only to resuscitation preferences, not to all other medical care【18】.
Shared decision‑making with a competent patient should include: (1) reaffirmation that the DNR order remains in effect, (2) clarification that dialysis is a separate therapeutic intervention, (3) discussion of risks, benefits, and alternatives to dialysis, and (4) exploration of the patient’s goals of care and quality‑of‑life priorities【17】【20】【19】.
The European Society of Cardiology emphasizes that open, sensitive communication enables advanced planning and respects patients’ fears, concerns, and wishes【21】.

Clinical Recommendations for Hyperkalemia Management in ESRD

Urgent dialysis (or CRRT in unstable patients) should be initiated promptly for severe hyperkalemia in ESRD, regardless of DNR status, because it corrects a reversible, life‑threatening electrolyte abnormality【19】【20】.
The DNR status should never prevent treatment of reversible acute conditions such as hyperkalemia【18】.

Common Misconceptions and Pitfalls

Do not assume that a DNR order mandates withholding all aggressive treatments; it only restricts cardiopulmonary resuscitation【17】【18】.
Avoid conflating resuscitation preferences with broader treatment preferences; they are distinct clinical decisions【17】.
Delaying urgent treatment of life‑threatening conditions like severe hyperkalemia can create self‑fulfilling prophecies of poor outcomes【17】.

Calcium Administration Precautions and Dosing in Hyperkalemia

IV Compatibility and Safety

Do not mix calcium preparations with sodium bicarbonate in the same IV line because co‑administration can cause precipitation, potentially compromising infusion safety and patient outcomes. 22
Exercise caution when administering calcium to patients with elevated serum phosphate (e.g., tumor‑lysis syndrome), as the combination raises the risk of calcium‑phosphate precipitation in tissues and may lead to obstructive uropathy. 22

Pediatric Dosing Recommendations

For children with hyperkalemia, give calcium gluconate 100–200 mg/kg (or calcium chloride 20 mg/kg, equivalent to 0.2 mL/kg of 10 % solution) as a slow IV infusion, with continuous ECG monitoring to detect possible bradycardia. This dosing provides temporary cardiac membrane protection while definitive potassium‑lowering therapies are initiated. 22

Tumor‑Lysis Syndrome Considerations

In patients with tumor‑lysis syndrome who develop symptomatic hypocalcemia, administer calcium cautiously at 50–100 mg/kg IV, but avoid calcium if serum phosphate is elevated to prevent calcium‑phosphate precipitation and related complications. 22

Nebulized Salbutamol in Acute Hyperkalemia Management

Dosing Protocol

Standard dose: Administer 10–20 mg salbutamol via nebulizer in 4 mL over 10–15 minutes to shift potassium intracellularly. 23

Integration into Treatment Algorithm

Cardiac Membrane Stabilization

Calcium therapy: Give calcium gluconate 10 % (15–30 mL) or calcium chloride 10 % (5–10 mL) IV over 2–5 minutes; onset 1–3 minutes, duration 30–60 minutes, and it does not lower serum potassium. 23

Intracellular Potassium Shift (administer simultaneously)

Insulin‑glucose: Infuse 10 units regular insulin IV with 25 g dextrose (≈50 mL D50W) over 15–30 minutes. 23
Nebulized salbutamol: Deliver 10–20 mg salbutamol nebulized over 10–15 minutes as part of the same shift regimen. 23
Sodium bicarbonate (if metabolic acidosis): Give 50 mEq sodium bicarbonate IV over 5 minutes only when pH < 7.35 and bicarbonate < 22 mEq/L. 23

Definitive Potassium Removal

Hemodialysis: Indicated for severe hyperkalemia, oliguria, end‑stage renal disease, or refractory cases. 23

Safety Profile

Common Side Effects

Sinus tachycardia: Modest increase in heart rate is the most frequently observed adverse effect of nebulized salbutamol. 23

Monitoring Requirements

Cardiac monitoring: Continuous ECG monitoring during and after nebulized salbutamol administration.
Potassium reassessment: Re‑measure serum potassium 1–2 hours after treatment and repeat checks every 2–4 hours until stable. 23

Calcium Gluconate Use in Malignant Hyperthermia‑Related Hyperkalemia

Special Clinical Scenario

In patients who develop hyperkalemia secondary to malignant hyperthermia, calcium gluconate should be given only as an extreme, life‑saving measure because the influx of extracellular calcium can worsen intracellular calcium overload and aggravate muscle injury. 24
For malignant hyperthermia‑associated hyperkalemia, the preferred immediate interventions are sodium bicarbonate and insulin‑glucose therapy rather than calcium gluconate, to avoid the risk of calcium‑mediated toxicity. 24